LiT4™
TLR4 in a Liposome
Liposomes consist of vesicles formed by the assembly of phospholipid bilayers. These vesicles can be made at ~100 nm diameters and have good stability. Liposomes are versatile and biocompatible vehicles for adjuvant formulation. As an amphiphilic molecule, the TLR4 agonist will be localized within the lipid bilayer. Furthermore, aqueous adjuvants such as QS21 can be encapsulated in the aqueous interior of the liposomes or solubilized in the aqueous bulk phase forming an adjuvant like the established adjuvant AS01B which has demonstrated good results in malaria, shingles, and TB.
Sold in a vial of 0.5 mL.
Research-grade only. Inquire about cGMP.
$325.00
LiT4™ is a TLR4 agonist in a liposomal formulation of about 100 nm in average diameter. The TLR4 agonist produces a potent, balanced immune response with a TH1 bias. Each 0.5 mL vial contains 5o µg TLR agonist.
LiT4™
TLR4 in a Liposome
Liposomes consist of vesicles formed by the assembly of phospholipid bilayers. These vesicles can be made at ~100 nm diameters and have good stability. Liposomes are versatile and biocompatible vehicles for adjuvant formulation. As an amphiphilic molecule, the TLR4 agonist will be localized within the lipid bilayer. Furthermore, aqueous adjuvants such as QS21 can be encapsulated in the aqueous interior of the liposomes or solubilized in the aqueous bulk phase forming an adjuvant like the established adjuvant AS01B which has demonstrated good results in malaria, shingles, and TB.
Sold in a vial of 0.5 mL.
Research-grade only. Inquire about cGMP.
Related products
LiT4™ is a TLR4 agonist in a liposomal formulation of about 100 nm in average diameter. The TLR4 agonist produces a potent, balanced immune response with a TH1 bias. Each 0.5 mL vial contains 5o µg TLR agonist.
LiT4™
TLR4 in a Liposome
Liposomes consist of vesicles formed by the assembly of phospholipid bilayers. These vesicles can be made at ~100 nm diameters and have good stability. Liposomes are versatile and biocompatible vehicles for adjuvant formulation. As an amphiphilic molecule, the TLR4 agonist will be localized within the lipid bilayer. Furthermore, aqueous adjuvants such as QS21 can be encapsulated in the aqueous interior of the liposomes or solubilized in the aqueous bulk phase forming an adjuvant like the established adjuvant AS01B which has demonstrated good results in malaria, shingles, and TB.
Sold in a vial of 0.5 mL.
Research-grade only. Inquire about cGMP.
Related products
LiT4™ is a TLR4 agonist in a liposomal formulation of about 100 nm in average diameter. The TLR4 agonist produces a potent, balanced immune response with a TH1 bias. Each 0.5 mL vial contains 5o µg TLR agonist.
LiT4™
TLR4 in a Liposome
Liposomes consist of vesicles formed by the assembly of phospholipid bilayers. These vesicles can be made at ~100 nm diameters and have good stability. Liposomes are versatile and biocompatible vehicles for adjuvant formulation. As an amphiphilic molecule, the TLR4 agonist will be localized within the lipid bilayer. Furthermore, aqueous adjuvants such as QS21 can be encapsulated in the aqueous interior of the liposomes or solubilized in the aqueous bulk phase forming an adjuvant like the established adjuvant AS01B which has demonstrated good results in malaria, shingles, and TB.
Sold in a vial of 0.5 mL.
Research-grade only. Inquire about cGMP.
Related products
Recently Viewed Items
You haven't viewed at any of the products yet.